Clinical pharmacokinetics of docetaxel : recent developments (Q36410396)

14 August 2017

1 reference

title

Clinical pharmacokinetics of docetaxel : recent developments (English)

1 reference

14 August 2017

1 reference

1 reference

2

Alex Sparreboom

1 reference

14 August 2017

Sharyn D Baker

1

1 reference

ORCID Public Data File 2021

Jaap Verweij

series ordinal

3

object named as

Jaap Verweij

1 reference

14 August 2017

1 January 2006

1 reference

Clinical Pharmacokinetics

14 August 2017

1 reference

14 August 2017

45

1 reference

14 August 2017

3

1 reference

14 August 2017

235-252

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200645030-00002

14 August 2017

0 references

cites work

Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction

1 reference

12 December 2020

Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method

1 reference

12 December 2020

The genetic determinants of the CYP3A5 polymorphism

1 reference

12 December 2020

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies

1 reference

12 December 2020

Genetic variability in CYP3A5 and its possible consequences.

1 reference

12 December 2020

Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours

1 reference

12 December 2020

Clinical pharmacokinetics of docetaxel.

1 reference

12 December 2020

Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver

1 reference

12 December 2020

Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.

1 reference

12 December 2020

Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors

1 reference

12 December 2020

"Inactive" excipients such as Cremophor can affect in vivo drug disposition

1 reference

12 December 2020

Population pharmacokinetics of weekly docetaxel in patients with advanced cancer

1 reference

12 December 2020

Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin.

1 reference

12 December 2020

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol

1 reference

12 December 2020

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of docetaxel and paclitaxel in human plasma and oral fluid

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer

1 reference

12 December 2020

Drug binding to human alpha-1-acid glycoprotein in health and disease

1 reference

12 December 2020

Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma

1 reference

12 December 2020

Genetic contribution to variable human CYP3A-mediated metabolism

1 reference

12 December 2020

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial

1 reference

12 December 2020

Weekly taxanes in metastatic breast cancer (review).

1 reference

12 December 2020

Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.

1 reference

12 December 2020

Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.

1 reference

12 December 2020

Docetaxel administration schedule: from fever to tears? A review of randomised studies

1 reference

12 December 2020

Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft

1 reference

12 December 2020

Isolation, purification and biological activity of major docetaxel metabolites from human feces.

1 reference

12 December 2020

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

12 December 2020

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel

1 reference

12 December 2020

A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies

1 reference

12 December 2020

Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy

1 reference

12 December 2020

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

1 reference

12 December 2020

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

1 reference

12 December 2020

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

1 reference

12 December 2020

Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity

1 reference

12 December 2020

Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model

1 reference

12 December 2020

Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches

1 reference

12 December 2020

A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors

1 reference

12 December 2020

Combination Treatment with Weekly Docetaxel and Gemcitabine for Advanced Non–Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status: Results of a Minnie Pearl Cancer Research Network Phase II Trial

1 reference

12 December 2020

Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer

1 reference

12 December 2020

A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro

1 reference

12 December 2020

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.

1 reference

12 December 2020

A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique

1 reference

12 December 2020

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

1 reference

12 December 2020

Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay

1 reference

12 December 2020

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

1 reference

12 December 2020

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

1 reference

12 December 2020

Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol

1 reference

12 December 2020

Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer

1 reference

12 December 2020

Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine

1 reference

12 December 2020

A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma

1 reference

12 December 2020

Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.

1 reference

12 December 2020

Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity

1 reference

12 December 2020

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

1 reference

12 December 2020

MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.

1 reference

12 December 2020

Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction

1 reference

12 December 2020

Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel

1 reference

12 December 2020

Orally active docetaxel analogue: synthesis of 10-deoxy-10-C-morpholinoethyl docetaxel analogues

1 reference

12 December 2020

Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences

1 reference

12 December 2020

Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer

1 reference

12 December 2020

The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors

1 reference

12 December 2020

Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization

1 reference

12 December 2020

Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein

1 reference

12 December 2020

Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel.

1 reference

12 December 2020

Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.

1 reference

12 December 2020

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes

1 reference

12 December 2020

A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor

1 reference

12 December 2020

Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results

1 reference

12 December 2020

Determination of fraction unbound docetaxel using microequilibrium dialysis

1 reference

12 December 2020

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid

1 reference

12 December 2020

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

1 reference

12 December 2020

Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry

1 reference

12 December 2020

Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients

1 reference

12 December 2020

The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

1 reference

12 December 2020

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

1 reference

12 December 2020

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

12 December 2020

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

12 December 2020

Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry

1 reference

12 December 2020

The pharmacological role of P-glycoprotein in the intestinal epithelium.

1 reference

12 December 2020

CYP3A4 and the erythromycin breath test.

1 reference

12 December 2020

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins

1 reference

12 December 2020

The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance

1 reference

12 December 2020

Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule

1 reference

12 December 2020

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

12 December 2020

Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein

1 reference

12 December 2020

Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions

1 reference

12 December 2020

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?

1 reference

12 December 2020

Dexamethasone as a probe for docetaxel clearance.

1 reference

12 December 2020

Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study

1 reference

12 December 2020

Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial

1 reference

12 December 2020

Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study

1 reference

12 December 2020

RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4

1 reference

12 December 2020

Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.

1 reference

12 December 2020

Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer

1 reference

12 December 2020

Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).

1 reference

12 December 2020

Intraperitoneal taxanes

1 reference

12 December 2020

Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects

1 reference

12 December 2020

Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients

1 reference

12 December 2020

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

12 December 2020

BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy

1 reference

12 December 2020

Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel

1 reference

12 December 2020

The discovery of BMS-275183: an orally efficacious novel taxane

1 reference

12 December 2020

Phase I study of docetaxel and topotecan in patients with solid tumors

1 reference

12 December 2020

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

12 December 2020

Taxanes in elderly breast cancer patients

1 reference

12 December 2020

Relationship of systemic exposure to unbound docetaxel and neutropenia.

1 reference

12 December 2020

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.

1 reference

12 December 2020

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

1 reference

12 December 2020

A sensitive docetaxel assay in plasma by solid-phase extraction and high performance liquid chromatography-UV detection: validation and suitability in phase I clinical trial pharmacokinetics

1 reference

12 December 2020

Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry

1 reference

12 December 2020

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

1 reference

12 December 2020

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

1 reference

12 December 2020

Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies

1 reference

12 December 2020

In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam

1 reference

12 December 2020

Factors affecting cytochrome P-450 3A activity in cancer patients.

1 reference

12 December 2020

Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel

1 reference

12 December 2020

Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance

1 reference

12 December 2020

Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir

1 reference

12 December 2020

A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies

1 reference

12 December 2020

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

12 December 2020

Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer

1 reference

12 December 2020

Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response

1 reference

12 December 2020

Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance

1 reference

12 December 2020

Oral delivery of taxanes

1 reference

12 December 2020

Docetaxel: promising and novel combinations in ovarian cancer

1 reference

12 December 2020

Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview

1 reference

12 December 2020

10.2165/00003088-200645030-00002

Identifiers

DOI

1 reference

PubMed ID

16509758

Dimensions Publication ID

14 August 2017

0 references

1 reference

PubMed ID

16509758